CSF3R colony stimulating factor 3 receptor
ENSG00000119535 · protein coding · Open Targets profile
Receptor for granulocyte colony-stimulating factor (CSF3), essential for granulocytic maturation. Plays a crucial role in the proliferation, differentiation and survival of cells along the neutrophilic lineage. In addition it may function in some adhesion or recognition events at the cell surface. .
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Antibody
- UniProt loc high conf, GO CC high conf, UniProt SigP or TMHMM
- PROTAC
- Database Ubiquitination
- Other modalities
- Approved Drug
gnomAD loss of function constraint: o/e 0.6159800291061401 (upper bound 0.7760800123214722). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 400 registry trials, updated in the last three years, of the most advanced drugs against CSF3R (balugrastim, lipegfilgrastim, efbemalenograstim alfa, pegteograstim, lenograstim, eflapegrastim, regramostim, anumigilimab), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- George SomloCity of Hope Medical Center · 3 of 3 trials Phase 2+
- Suk S De RavinNational Institute of Allergy and Infectious Diseases (NIAID) · 3 of 3 trials Phase 2+
- Brandon TriplettSt. Jude Children's Research Hospital · 2 of 3 trials Phase 2+Ph2NCT03849651 · TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignanciesbrief
- Aditi BagchiSt. Jude Children's Research Hospital · 2 of 2 trials Phase 2+
- Akshay SharmaSt. Jude Children's Research Hospital · 2 of 2 trials Phase 2+
- Alex F HerreraSWOG Cancer Research Network · 2 of 2 trials Phase 2+
- Christopher G KanakryNational Cancer Institute (NCI) · 2 of 2 trials Phase 2+
- Courtney F JosephNational Heart, Lung, and Blood Institute (NHLBI) · 2 of 2 trials Phase 2+
- Daihong LiuChinese PLA General Hospital · 2 of 2 trials Phase 2+
- Issa F KhouriM.D. Anderson Cancer Center · 2 of 2 trials Phase 2+
- John F TisdaleNational Heart, Lung, and Blood Institute (NHLBI) · 2 of 2 trials Phase 2+
- Nirav ShahMedical College of Wisconsin · 2 of 2 trials Phase 2+
- Phuong VoFred Hutchinson Cancer Center · 2 of 2 trials Phase 2+
- Qaiser BashirM.D. Anderson Cancer Center · 2 of 2 trials Phase 2+
- Rachel B. SalitFred Hutch/University of Washington Cancer Consortium · 2 of 2 trials Phase 2+
Registry trials of balugrastim, lipegfilgrastim, efbemalenograstim alfa, pegteograstim, lenograstim, eflapegrastim, regramostim, anumigilimab updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 317 of 378 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 22 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
280 trials of drugs against CSF3R were stopped early; 22 of the 200 most recent give no reason
Terminated, withdrawn and suspended interventional trials of balugrastim, lipegfilgrastim, efbemalenograstim alfa, pegteograstim, lenograstim, eflapegrastim, regramostim, anumigilimab, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 25 most recent of 280.
- terminated · 2026-10-21 · Medical College of Wisconsin · matched by the registry's drug synonyms“No longer have funding support to complete the pharmacogenetics component.”
- terminated · 2026-10-16 · CellProthera · Lenograstim“Strategic change”
- suspended · 2026-09-29 · University of Washington · matched by the registry's drug synonyms“Safety Review”
- terminated · 2026-08-24 · University of Michigan Rogel Cancer Center · matched by the registry's drug synonyms“Interim Analysis per Protocol”
- terminated · 2026-06-24 · National Cancer Institute (NCI) · matched by the registry's drug synonyms“The study was targeted to accrue 130 patients, but closed early for futility.”
- terminated · 2026-06-01 · Northwestern University · matched by the registry's drug synonyms“Low accrual”
- withdrawn · 2026-05-07 · M.D. Anderson Cancer Center · matched by the registry's drug synonyms“PI requested”
- terminated · 2026-04-24 · European Society for Blood and Marrow Transplantation · matched by the registry's drug synonyms“Ceased production of the study drug, Lymphoglobulin. Recruitment of patients onto the trial was too slow.”
- terminated · 2026-04-16 · UNC Lineberger Comprehensive Cancer Center · matched by the registry's drug synonyms“Funding”
- terminated · 2026-04-15 · M.D. Anderson Cancer Center · matched by the registry's drug synonyms“<75% participation”
- terminated · 2026-03-24 · Hackensack Meridian Health · matched by the registry's drug synonyms“Lack of Accrual”
- withdrawn · 2026-02-24 · Ossium Health, Inc. · matched by the registry's drug synonyms“Change in Study Design”
- withdrawn · 2026-02-13 · M.D. Anderson Cancer Center · matched by the registry's drug synonyms“No participants enrolled”
- withdrawn · 2026-01-15 · Camillo Ricordi and Jay Skyler · matched by the registry's drug synonyms“Study withdrawn prior to enrollment due to funding issues”
- terminated · 2026-01-05 · Astellas Pharma Global Development, Inc. · matched by the registry's drug synonyms“The study was terminated due to enrollment challenges.”
- terminated · 2025-12-18 · EMD Serono Research & Development Institute, Inc. · matched by the registry's drug synonyms“Sponsor Decision”
- withdrawn · 2025-12-01 · National Institute of Allergy and Infectious Diseases (NIAID) · matched by the registry's drug synonyms“Lack of accrual”
- terminated · 2025-09-23 · Sutro Biopharma, Inc. · matched by the registry's drug synonyms“Due to strategic business considerations, Sutro has deprioritized the development of luveltamab tazevibulin, leading to termination of the REFRaME program. This decision is not related to any safety or efficacy concerns associated with luvelta”
- terminated · 2025-09-09 · Sanofi · matched by the registry's drug synonyms“Study was prematurely stopped due to sponsor decision (stage 2 efficacy criteria not met); not due to safety concerns.”
- terminated · 2025-08-28 · Seagen Inc. · matched by the registry's drug synonyms“The study was prematurely discontinued as the sponsor believes the data collected is enough to show the safety and efficacy of the combinations studied in all cohorts. The decision was not based on any safety and/or efficacy concerns.”
- terminated · 2025-08-11 · M.D. Anderson Cancer Center · matched by the registry's drug synonyms“The study was terminated early due to slow enrollment.”
- withdrawn · 2025-08-07 · Jiangsu HengRui Medicine Co., Ltd. · matched by the registry's drug synonyms“The sponsor's R\&D strategy is adjusted.”
- terminated · 2025-05-29 · Gilead Sciences · matched by the registry's drug synonyms“Study terminated early due to the magrolimab program discontinuation.”
- terminated · 2025-05-23 · M.D. Anderson Cancer Center · matched by the registry's drug synonyms“supporting/funding source decided to de-prioritize and stop development of DS-1594”
- terminated · 2025-04-23 · Stanford University · matched by the registry's drug synonyms“Lack of funding”
Paediatric incentives and obligations for CSF3R's drugs
For balugrastim, lipegfilgrastim, efbemalenograstim alfa, pegteograstim, lenograstim, eflapegrastim, regramostim, anumigilimab: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · CSF3R is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: yes · EMEA-001019-PIP01-10-M05 (lipegfilgrastim, Prevention of chemotherapy-induced febrile neutropenia;Treatment of chemotherapy-induced neutropenia): PM: decision on the application for modification of an agreed PIP, 29 Jan 2020; compliance positive 30 Apr 2020; EMEA-002385-PIP01-18 (Eflapegrastim, Treatment of chemotherapy-induced neutropenia): PM: decision on the application for modification of an agreed PIP, 8 Oct 2018Rule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: no · No EU orphan designation names balugrastim, lipegfilgrastim, efbemalenograstim alfa, pegteograstim, lenograstim, eflapegrastim, regramostim, anumigilimabRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: yes · Ryzneuta: authorised since 21 Mar 2024; Lonquex: authorised since 25 Jul 2013Rule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of balugrastim, lipegfilgrastim, efbemalenograstim alfa, pegteograstim, lenograstim, eflapegrastim, regramostim, anumigilimabRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-12
- Registered studies open to children: yes · 660 interventional studies of balugrastim, lipegfilgrastim, efbemalenograstim alfa, pegteograstim, lenograstim, eflapegrastim, regramostim, anumigilimab include patients under 18; 83 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-12
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 10 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.